These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 36774991)

  • 21. Cancer immunotherapy targeting the CD47/SIRPα axis.
    Weiskopf K
    Eur J Cancer; 2017 May; 76():100-109. PubMed ID: 28286286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells.
    Ponce LP; Fenn NC; Moritz N; Krupka C; Kozik JH; Lauber K; Subklewe M; Hopfner KP
    Oncotarget; 2017 Feb; 8(7):11284-11301. PubMed ID: 28061465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CD47-SIRPα blocking-based immunotherapy: Current and prospective therapeutic strategies.
    Bouwstra R; van Meerten T; Bremer E
    Clin Transl Med; 2022 Aug; 12(8):e943. PubMed ID: 35908284
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The expression profiles of CD47 in the tumor microenvironment of salivary gland cancers: a next step in histology-driven immunotherapy.
    Votava M; Bartolini R; Capkova L; Smetanova J; Jiri V; Kuchar M; Kalfert D; Plzak J; Bartunkova J; Strizova Z
    BMC Cancer; 2022 Sep; 22(1):1021. PubMed ID: 36171566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD47 Blockade Inhibits Tumor Progression through Promoting Phagocytosis of Tumor Cells by M2 Polarized Macrophages in Endometrial Cancer.
    Gu S; Ni T; Wang J; Liu Y; Fan Q; Wang Y; Huang T; Chu Y; Sun X; Wang Y
    J Immunol Res; 2018; 2018():6156757. PubMed ID: 30525058
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Blockade of dual immune checkpoint inhibitory signals with a CD47/PD-L1 bispecific antibody for cancer treatment.
    Wang R; Zhang C; Cao Y; Wang J; Jiao S; Zhang J; Wang M; Tang P; Ouyang Z; Liang W; Mao Y; Wang A; Li G; Zhang J; Wang M; Wang S; Gui X
    Theranostics; 2023; 13(1):148-160. PubMed ID: 36593962
    [No Abstract]   [Full Text] [Related]  

  • 27. Blocking "don't eat me" signal of CD47-SIRPα in hematological malignancies, an in-depth review.
    Russ A; Hua AB; Montfort WR; Rahman B; Riaz IB; Khalid MU; Carew JS; Nawrocki ST; Persky D; Anwer F
    Blood Rev; 2018 Nov; 32(6):480-489. PubMed ID: 29709247
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DSP107 combines inhibition of CD47/SIRPα axis with activation of 4-1BB to trigger anticancer immunity.
    Cendrowicz E; Jacob L; Greenwald S; Tamir A; Pecker I; Tabakman R; Ghantous L; Tamir L; Kahn R; Avichzer J; Aronin A; Amsili S; Zorde-Khvalevsky E; Gozlan Y; Vlaming M; Huls G; van Meerten T; Dranitzki ME; Foley-Comer A; Pereg Y; Peled A; Chajut A; Bremer E
    J Exp Clin Cancer Res; 2022 Mar; 41(1):97. PubMed ID: 35287686
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting the myeloid checkpoint receptor SIRPα potentiates innate and adaptive immune responses to promote anti-tumor activity.
    Kuo TC; Chen A; Harrabi O; Sockolosky JT; Zhang A; Sangalang E; Doyle LV; Kauder SE; Fontaine D; Bollini S; Han B; Fu YX; Sim J; Pons J; Wan HI
    J Hematol Oncol; 2020 Nov; 13(1):160. PubMed ID: 33256806
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD47/SIRPα pathway mediates cancer immune escape and immunotherapy.
    Jia X; Yan B; Tian X; Liu Q; Jin J; Shi J; Hou Y
    Int J Biol Sci; 2021; 17(13):3281-3287. PubMed ID: 34512146
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinicopathological analysis of immunohistochemical expression of CD47 and SIRPα in adult T-cell leukemia/lymphoma.
    Yanagida E; Miyoshi H; Takeuchi M; Yoshida N; Nakashima K; Yamada K; Umeno T; Shimasaki Y; Furuta T; Seto M; Ohshima K
    Hematol Oncol; 2020 Dec; 38(5):680-688. PubMed ID: 32569413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD47 Ligation Repositions the Inhibitory Receptor SIRPA to Suppress Integrin Activation and Phagocytosis.
    Morrissey MA; Kern N; Vale RD
    Immunity; 2020 Aug; 53(2):290-302.e6. PubMed ID: 32768386
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD47-signal regulatory protein α signaling system and its application to cancer immunotherapy.
    Murata Y; Saito Y; Kotani T; Matozaki T
    Cancer Sci; 2018 Aug; 109(8):2349-2357. PubMed ID: 29873856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanoparticle-Mediated CD47-SIRPα Blockade and Calreticulin Exposure for Improved Cancer Chemo-Immunotherapy.
    Luo JQ; Liu R; Chen FM; Zhang JY; Zheng SJ; Shao D; Du JZ
    ACS Nano; 2023 May; 17(10):8966-8979. PubMed ID: 37133900
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD47-SIRPα-targeted therapeutics: status and prospects.
    Maute R; Xu J; Weissman IL
    Immunooncol Technol; 2022 Mar; 13():100070. PubMed ID: 35754851
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The overall potential of CD47 in cancer immunotherapy: with a focus on gastrointestinal tumors.
    Tzatzarakis E; Hissa B; Reissfelder C; Schölch S
    Expert Rev Anticancer Ther; 2019 Nov; 19(11):993-999. PubMed ID: 31686549
    [No Abstract]   [Full Text] [Related]  

  • 37. CD47-SIRPα Controls ADCC Killing of Primary T Cells by PMN Through a Combination of Trogocytosis and NADPH Oxidase Activation.
    Gondois-Rey F; Miller T; Laletin V; Morelli X; Collette Y; Nunès J; Olive D
    Front Immunol; 2022; 13():899068. PubMed ID: 35795660
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
    Jia D; Lu Y; Lv M; Wang F; Lu X; Zhu W; Wei J; Guo W; Liu R; Li G; Wang R; Li J; Yuan F
    J Control Release; 2023 Aug; 360():858-871. PubMed ID: 37473808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma.
    Xiao A; Akilov OE
    Cells; 2022 Nov; 11(22):. PubMed ID: 36429020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The CD47-SIRPα Immune Checkpoint.
    Logtenberg MEW; Scheeren FA; Schumacher TN
    Immunity; 2020 May; 52(5):742-752. PubMed ID: 32433947
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.